{
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "document": {
    "pdf_name": "Liu_et_al.__2024_"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "The RIV4 group had the highest A (H1 N1) pdm09 HA stalk and A (H3 N2) HA stalk antibodies at 1 month post vaccination, however the fold rises of HA stalk antibodies were low (<1.8) and similar among all 4 vaccine groups (Fig. 4 D).",
      "relevance_explanation": "This quote shows that the recombinant HA vaccine (RIV4) induced the highest levels of HA stalk antibodies, which are broadly cross-reactive and target conserved regions, supporting the claim that BEVS-produced HA antigens induce higher levels of such antibodies compared to egg-derived vaccines.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Comparing pre- and 1 month post vaccination, A (H3 N2) HA stalk binding antibodies were significantly boosted in ccIIV4-RIV4, RIV4-RIV4, IIV4-ccIIV4, and IIV4-RIV4 arms, while A (H1 N1) pdm09 HA stalk binding antibodies were also significantly boosted in ccIIV4-ccIIV4 and RIV4-ccIIV4 arms (Fig. 8 C).",
      "relevance_explanation": "This quote demonstrates that regimens including RIV4 (recombinant HA) significantly boosted HA stalk binding antibodies, which are broadly cross-reactive and target conserved regions, supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}